Edition:
United Kingdom

PAION AG (PA8G.DE)

PA8G.DE on Xetra

2.47EUR
9:48am GMT
Change (% chg)

€0.02 (+0.73%)
Prev Close
€2.45
Open
€2.43
Day's High
€2.51
Day's Low
€2.43
Volume
8,842
Avg. Vol
156,897
52-wk High
€3.53
52-wk Low
€2.15

Latest Key Developments (Source: Significant Developments)

PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - PAION AG :‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT.‍NO SECOND INTRANASAL STUDY REQUIRED​.‍ASSUMES CLINICAL DEVELOPMENT PROGRAM FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN U.S. AS COMPLETED​.  Full Article

PAION ‍9-mth net loss at 8.5 mln euros
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - PAION AG :DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017.‍CASH POSITION OF EUR 29.6 MILLION AS OF 30 SEPTEMBER 2017​.‍REVENUES IN FIRST NINE MONTHS OF 2017 AMOUNTED TO KEUR 5,097 COMPARED TO KEUR 2,230 IN PRIOR-YEAR PERIOD​.‍RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO KEUR 13,528 IN FIRST NINE MONTHS OF 2017​.‍9MTH NET LOSS AMOUNTED TO KEUR 8,508. IN PRIOR-YEAR PERIOD, A NET LOSS OF KEUR 16,061 WAS REPORTED​.‍CONFIRMS ITS OUTLOOK FOR FY ANNOUNCED ON 09 AUGUST 2017 WITH PUBLICATION OF HALF-YEAR RESULTS FOR 2017​.  Full Article

Paion: Japan patent office grants dosing patent for remimazolam
Friday, 13 Oct 2017 

Oct 13 (Reuters) - PAION AG ::DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN.‍PATENT PROTECTION UNTIL 2033 IN JAPANESE MARKET​.  Full Article

Paion H1 net loss widens to 13.2 million euros
Wednesday, 10 Aug 2016 

Paion AG : In first half of 2016, revenues were 0.2 million euros ($222,980.00) . Expects revenues of approx. 4 million euros in 2016, which is portion of 10 million euros upfront payment received from Cosmo that will be recognized as revenues in 2016 . Expects research and development expenses to be between 24 million euros and 27 million euros depending on progress of development for FY . Net loss was 13.2 million euros for first half-year 2016 compared to a loss of 11.3 million euros for prior-year period .Net loss is expected to be between 21.5 million euros and 24 million euros, a decrease compared to previous year (2015: 28.2 million euros) for FY.  Full Article

Paion, unit of Cosmo Pharmaceuticals enter into license deal for Remimazolam
Friday, 24 Jun 2016 

Paion Ag : Co and Cosmo Technologies Ltd, unit of Cosmo Pharmaceuticals NV, entered into license agreement for Remimazolam . Under license agreement, Paion will receive a eur 10 million upfront licence fee payment .Another unit of Cosmo entered into investment agreement with co, pursuant to which it has committed to invest eur 10 mln in shares of co.  Full Article

Paion reports positive remimazolam headline data in phase III study in procedural sedation for colonoscopy
Monday, 20 Jun 2016 

PAION AG :Said on Sunday remimazolam met its primary efficacy endpoint in the first study of its pivotal U.S. Phase III program in patients undergoing procedural sedation.  Full Article

Paion Q1 net loss widens to 6.73 million euros
Wednesday, 11 May 2016 

Paion AG : Q1 net loss for Q1 2016 amounted to 6.729 million euros ($7.66 million), in the prior-year period, a net loss of 4.703 million euros was reported . Cash and cash equivalents decreased by 7.218 million euros in Q1 2016 . Confirms its outlook for 2016 made on 22 March 2016 with publication of annual financial results for 2015 . Research and development expenses amounted to 6.502 million euros in Q1 2016 and relate to remimazolam .As expected, no significant revenues were realized in Q1 2016.  Full Article

Paion gives FY 2016 outlook below analysts' estimates
Tuesday, 22 Mar 2016 

Paion AG:FY 2016 net loss is expected to decrease compared to prior year and to amount to approx. 24.5 million euros to 27.5 million euros.Does not expect revenues in FY 2016 as Remimazolam is still in development stage.FY 2016 net loss estimate 21.52 million euros - Thomson Reuters I/B/E/S.FY 2016 revenue estimate 2.03 million euros - Thomson Reuters I/B/E/S.  Full Article

Paion AG discontinues European Remimazolam Phase 3 trial
Tuesday, 9 Feb 2016 

Paion AG:Discontinues European Remimazolam Phase III trial in cardiac surgery patients due to insufficient recruitment.  Full Article

BRIEF-PAION announces clinical development progress with remimazolam

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER HANA PHARM IN SOUTH KOREA